Combinations and Treatment Sequence Strategies in Breast Cancer
July 22nd 2024In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.
Read More
PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
July 22nd 2024The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.
Read More
PIK3CA Mutations and Delivering PI3K Inhibitors
July 15th 2024In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.
Read More
Case Presentation 2: Co-mutations in ESR1 and PIK3CA
July 15th 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, discuss the clinical presentation and management of a 64-year-old postmenopausal female with a history of rheumatoid arthritis who was diagnosed with stage IV, grade 3, invasive ductal carcinoma in her left breast, taking into account her comorbidities and the advanced stage of her breast cancer.
Read More
Evolving Best Practices for ESR1 Testing
July 8th 2024The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.
Read More
EMERALD Study Design and Results for Elacestrant
July 8th 2024Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.
Read More
Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
July 1st 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.
Read More
Dynamics of ESR1 Alterations and Serial Liquid Biopsies
July 1st 2024In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.
Read More
Evolution of Testing Strategies for ESR1
June 25th 2024The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.
Read More
Prevalence and Testing Strategies for ESR1
June 25th 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.
Read More
Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions
June 24th 2024Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
Read More
Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.
Read More
Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.
Read More
TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
June 10th 2024Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
Read More
Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
June 3rd 2024Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.
Read More
Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
May 20th 2024Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.
Read More
The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
May 20th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.
Read More
Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer
October 23rd 2023Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.
Read More
The Future of HER2+ Breast Cancer Treatment
Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Read More
Patient Profile 3: Metastatic HER2+ BC
Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.
Read More
Patient Profile 2: Early Stage HER2+/HR- BC
Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.
Read More
Patient Profile 1: Early Stage HER2+/HR+ BC
Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.
Read More
Typical Approaches for Treatment Selection in the Third Line and Beyond
Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.
Read More
HER2+ mBC: Emerging Agents in the Third-Line and Higher Setting
Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.
Read More